JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease

(2016) J. Hutcheson et al.   CLINICAL CANCER RESEARCH

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma

(2016) Wei Ju et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection

(2016) Koichiro Haruki et al.   WORLD JOURNAL OF SURGERY

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model

(2016) Nadia M. Luheshi et al.   Oncotarget

STAT3 inhibition for cancer therapy: Cell-autonomous effects only?

(2016) Guido Kroemer et al.   OncoImmunology

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

Targeting the Inactive Conformation of JAK2 in Hematological Malignancies

(2015) Olli Silvennoinen et al.   CANCER CELL

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

(2015) Ramona Crescenzo et al.   CANCER CELL

STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells

(2015) Heng Yang et al.   CANCER RESEARCH

Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity

(2015) Kiyoshi Hirahara et al.   IMMUNITY

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities

(2015) Elisabeth Losdyck et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

(2015) Herbert I. Hurwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases

(2015) Daniella M. Schwartz et al.   Nature Reviews Rheumatology

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2–dependent adult T-cell leukemia

(2015) Meili Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+T cells

(2015) Chi-Keung Wan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

(2015) David Hong et al.   Science Translational Medicine

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer

(2015) Manish R. Patel et al.   Oncotarget

Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes

(2015) Kelly E. Craven et al.   Oncotarget

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma

(2015) Shuqun Yang et al.   Oncotarget

TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis

(2015) Jesse Gore et al.   Oncotarget

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

(2015) Therese Phillips et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Editorial: Decernotinib: A Next-Generation Jakinib

(2015) Massimo Gadina et al.   Arthritis & Rheumatology

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

(2015) R. Winograd et al.   Cancer Immunology Research

IFN  Induces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer

(2015) K. Bardhan et al.   Cancer Immunology Research

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

(2015) Roberto Bellucci et al.   OncoImmunology

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

(2014) S. Spoerl et al.   BLOOD

Mechanisms of Jak/STAT Signaling in Immunity and Disease

(2014) Alejandro V. Villarino et al.   JOURNAL OF IMMUNOLOGY

Cancer-related inflammation and treatment effectiveness

(2014) Connie I Diakos et al.   LANCET ONCOLOGY

Interleukin-21: a double-edged sword with therapeutic potential

(2014) Rosanne Spolski et al.   NATURE REVIEWS DRUG DISCOVERY

Interferons and Their Stimulated Genes in the Tumor Microenvironment

(2014) HyeonJoo Cheon et al.   SEMINARS IN ONCOLOGY

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

(2013) O. E. Rahma et al.   ANNALS OF ONCOLOGY

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

(2013) A. Quintas-Cardama et al.   CLINICAL CANCER RESEARCH

IL-21 Promotes CD8+ CTL Activity via the Transcription Factor T-bet

(2013) A. P. R. Sutherland et al.   JOURNAL OF IMMUNOLOGY

STAT3 Regulates Proliferation and Survival of CD8+T Cells: Enhances Effector Responses to HSV-1 Infection, and Inhibits IL-10+Regulatory CD8+T Cells in Autoimmune Uveitis

(2013) Cheng-Rong Yu et al.   MEDIATORS OF INFLAMMATION

The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signaling

(2013) Donald T Gracias et al.   NATURE IMMUNOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The immune network in pancreatic cancer development and progression

(2013) S M Wörmann et al.   ONCOGENE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) T. Seufferlein et al.   ANNALS OF ONCOLOGY

IFN R signaling mediates alloreactive T-cell trafficking and GVHD

(2012) J. Choi et al.   BLOOD

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells

(2012) Y. Wang et al.   CURRENT MOLECULAR MEDICINE

The JAK-STAT Pathway at Twenty

(2012) George R. Stark et al.   IMMUNITY

Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells

(2012) Rahul Purwar et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

(2012) Rita Andraos et al.   Cancer Discovery

Involvement of STAT3 in immune evasion during lung tumorigenesis

(2012) Hiroshi Kida et al.   OncoImmunology

A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma

(2011) Nigel B. Jamieson et al.   ANNALS OF SURGICAL ONCOLOGY

Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression

(2011) Akihisa Fukuda et al.   CANCER CELL

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis

(2011) R. B. Corcoran et al.   CANCER RESEARCH

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS